Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) – Research analysts at Wedbush issued their FY2026 earnings per share estimates for shares of Fate Therapeutics in a research note issued to investors on Thursday, May 5th. Wedbush analyst D. Nierengarten anticipates that the biopharmaceutical company will earn $0.65 per share for the year. Wedbush has a “Outperform” rating and a $77.00 price target on the stock.
Other equities analysts also recently issued reports about the stock. HC Wainwright cut their price objective on shares of Fate Therapeutics from $122.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, March 4th. Truist Financial lowered their target price on Fate Therapeutics from $125.00 to $75.00 in a research note on Wednesday, April 13th. StockNews.com upgraded Fate Therapeutics to a “sell” rating in a research note on Thursday, March 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Fate Therapeutics in a research note on Friday, April 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $87.22.
Fate Therapeutics (NASDAQ:FATE – Get Rating) last posted its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.08. The firm had revenue of $18.40 million for the quarter, compared to the consensus estimate of $9.01 million. Fate Therapeutics had a negative net margin of 379.89% and a negative return on equity of 30.25%. The business’s revenue for the quarter was up 65.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.48) EPS.
In other news, CEO J Scott Wolchko sold 30,000 shares of the company’s stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $35.00, for a total transaction of $1,050,000.00. Following the sale, the chief executive officer now directly owns 431,546 shares in the company, valued at $15,104,110. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Yu-Waye Chu sold 4,062 shares of the company’s stock in a transaction dated Tuesday, April 19th. The shares were sold at an average price of $35.37, for a total value of $143,672.94. Following the sale, the insider now owns 151,033 shares in the company, valued at $5,342,037.21. The disclosure for this sale can be found here. Insiders sold a total of 90,624 shares of company stock worth $3,270,224 over the last 90 days. 18.58% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently made changes to their positions in FATE. Raymond James & Associates increased its position in shares of Fate Therapeutics by 1.8% during the third quarter. Raymond James & Associates now owns 20,396 shares of the biopharmaceutical company’s stock valued at $1,209,000 after buying an additional 355 shares during the period. Swiss National Bank increased its position in shares of Fate Therapeutics by 0.5% during the third quarter. Swiss National Bank now owns 166,200 shares of the biopharmaceutical company’s stock valued at $9,851,000 after buying an additional 800 shares during the period. Mackenzie Financial Corp increased its position in shares of Fate Therapeutics by 68.8% during the third quarter. Mackenzie Financial Corp now owns 4,696 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 1,914 shares during the period. State Board of Administration of Florida Retirement System increased its position in shares of Fate Therapeutics by 0.6% during the third quarter. State Board of Administration of Florida Retirement System now owns 32,013 shares of the biopharmaceutical company’s stock valued at $1,897,000 after buying an additional 200 shares during the period. Finally, TD Asset Management Inc. grew its holdings in shares of Fate Therapeutics by 21.5% during the third quarter. TD Asset Management Inc. now owns 106,681 shares of the biopharmaceutical company’s stock worth $6,323,000 after purchasing an additional 18,871 shares in the last quarter.
Fate Therapeutics Company Profile (Get Rating)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
- Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE)
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.